Loading...

CNSP CNS PHARMACEUTICALS INC Management Changes 8-K Filing

CNS

CNSP

CNS PHARMACEUTICALS INC

(CNSP)

2026 8-K

Investor Presentation

Executive Changes

Management Changes

Management Change

Stockholder Approvals

Reverse Stock Split

Investor Meetings

Equity Offerings

Public Offering

Clinical Trial Update

Financial Update

Equity Offering

Earnings Report

Clinical Trial Update

Clinical Trial Update

Financial Update

Quantitative Data

Filing Letter with Quantita...

US FDA Inspection

Filing with Quantitative Data

Securities Purchase Agreements

Securities Purchase Agreements

Filing with Quantitative Data

Securities Purchase Agreements

Quantitative Data

Clinical Trial Update

Clinical Trial Update

Update on Berubicin Phase 2...

Public Offering

Update on Drug Candidate

Clinical Trial Update

Clinical Trial Update

Warrant Exercise

Other Special Situation

Management Changes

Clinical Trial Update

Clinical Trial Update

Earnings Reports

External Links:

CNS Pharmaceuticals, Inc. has appointed Steve O’Loughlin as the new Chief Financial Officer starting March 2, 2026, with an annual salary of $450,000 and a bonus potential of 40% of the base salary. Christopher Downs will transition to Senior Vice President – Finance on the same date, with a base salary of $350,000.

AI Assistant

CNS PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.